Moshe Spinowitz

Moshe Spinowitz

Partner, Tax

Moshe Spinowitz advises multinational companies in connection with cross-border mergers and acquisitions, and post-acquisition restructuring and integration transactions. He also represents clients on a range of tax controversy matters during all phases of IRS audits and appeals.


Mr. Spinowitz has advised several multinational companies on the integration and restructur­ing of their operations following large cross-border acquisitions. He also has counseled phar­maceutical and technology companies in connection with the structuring of their intellectual property holdings, as well as a variety of companies in connection with U.S. tax reform. Mr. Spinowitz also has successfully represented several multinational corporations before IRS appeals involving intercompany financing transactions and other cross-border tax matters.

Select representations include:

  • Bottomline Technologies in its pending $2.6 billion acquisition by Thomas Bravo;
  • Dicerna Pharmaceuticals in its $3.3 billion acquisition by Novo Nordisk;
  • Waldencast Acquisition Corp. in its pending business combination with Obagi Cosmeceuticals and Milk Makeup;
  • L’Occitane International in its acquisition of Sol de Janeiro Holdings;
  • AspenTech in its pending $11 billion combination with the industrial software business of Emerson Electric;
  • ArQule, Inc. in its $2.7 billion acquisition by a subsidiary of Merck & Co., Inc.;
  • Juno Therapeutics in its $9 billion acquisition by Celgene;
  • Clementia Pharmaceuticals Inc. in its $1.3 billion acquisition by Ipsen S.A.;
  • Gilead Sciences, Inc. in its $11.9 billion acquisition of Kite Pharma, its acquisition of Cell Design Labs for up to $567 million, and its research and development collaboration with, and equity investment in, Galapagos NV;
  • Biogen Inc. in the spin-off of its hemophilia business as an independent public company called Bioverativ;
  • Konecranes plc in its acquisition of Terex Corporation’s material handling and port solutions unit for $1.28 billion;
  • Merrimack Pharmaceuticals, Inc. in its sale of cancer treatment drugs Onivyde and generic Doxil to Ipsen S.A. for up to $1.025 billion; and
  • Spectra Energy Corp in its combination with Enbridge Inc. for $28 billion.

Mr. Spinowitz has been repeatedly selected for inclusion in Chambers USA and The Best Lawyers in America. Prior to joining Skadden, he served as a law clerk to Judge Michael Boudin on the U.S. Court of Appeals for the First Circuit, and Justice Antonin Scalia on the U.S. Supreme Court.



  • J.D., Harvard Law School, 2006 (magna cum laude; Articles Editor, Harvard Law Review)
  • B.A., Harvard College, 2002 (summa cum laude)


  • Massachusetts
  • District of Columbia


  • Law Clerk to Judge Michael Boudin, U.S. Court of Appeals for the First Circuit
  • Law Clerk to Associate Justice Antonin Scalia, U.S. Supreme Court

Moshe Spinowitz